

IN THE CLAIMS:

1. (Currently Amended) A chemically ~~synthesized~~ modified double stranded short interfering ~~nucleic ribonucleic~~ acid (siRNA) molecule comprising a sense strand and an antisense strand, wherein:
 - a. each strand of said siRNA molecule is about 18 to about 27 nucleotides in length;
 - b. the antisense strand of said siRNA molecule comprises about 18 to about 27 nucleotides that are nucleotide sequence that is complementary to a cholinergic receptor muscarinic 3 (CHRM3) nucleotide sequence comprising SEQ ID NO: 305; and the sense strand is complementary to the antisense strand; ~~and~~
 - c. the sense strand of the siRNA molecule comprises a portion of the CHRM3 nucleotide sequence of about 18 to about 27 nucleotides;
 - e. ~~said siRNA molecule is a 2'-deoxy-2'-fluoro-pyrimidine nucleotide.~~
 - d. between 50 and 100 percent of the nucleotide positions in one or both strands of the siRNA molecule are chemically modified; and
 - c. the antisense strand of the siRNA molecule comprises about 5, 6, 7, 8, 9, 10 or more 2'-O-methyl nucleotides.
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)

9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Previously Presented) The siRNA molecule of claim 1, wherein one or more purine nucleotides present in the sense strand are 2'-deoxy purine nucleotides.
15. (Canceled)
16. (Previously Presented) The siRNA molecule of claim 1, wherein the sense strand includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the sense strand.
17. (Previously Presented) The siRNA molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.
18. (Canceled)
19. (Previously Presented) The siRNA molecule of claim 1, wherein one or more purine nucleotides present in the antisense strand are 2'-O-methyl purine nucleotides.
20. (Previously Presented) The siRNA molecule of claim 1, wherein one or more purine nucleotides present in the antisense strand are 2'-deoxy- purine nucleotides.
21. (Previously Presented) The siRNA molecule of claim 1, wherein the antisense strand comprises a terminal phosphorothioate internucleotide linkage at the 3' end of the antisense strand.
22. (Canceled)
23. (Canceled)
24. (Canceled)

- 25. (Canceled)
- 26. (Canceled)
- 27. (Canceled)
- 28. (Canceled)
- 29. (Canceled)
- 30. (Previously Presented) The siRNA molecule of claim 1, wherein the 5'-end of the antisense strand includes a terminal phosphate group.
- 31. (Previously Presented) A composition comprising the siRNA molecule of claim 1 in a pharmaceutically acceptable carrier or diluent.